OZURDEX (dexamethasone) intravitreal implant by Allergan Allergan's Ozurdex (dexamethasone intravitreal implant) has been approved by the FDA for the treatment of macular edema following branch ...

A sustained-release dexamethasone device implanted during pars plana vitrectomy may be effective in pre-emptively reducing macular edema in patients with various underlying ocular diseases at risk for ...

Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss. Cost ...

Please provide your email address to receive an email when new articles are posted on . O teste clínico multicêntrico e randomizado inscreveu um total de 88 pacientes que foram divididos em dois ...

Allergan’s eye drug Ozurdex has been approved in the EU to treat a sight-threatening condition that affects people with diabetes. The European Commission granted marketing authorisation to Ozurdex, an ...

OZURDEX (dexamethasone) intravitreal implant by Allergan The FDA has approved Ozurdex (dexamethasone intravitreal implant, from Allergan) for the treatment of non-infectious ocular inflammation, or ...

The US Food and Drug Administration has approved Allergan's Ozurdex (dexamethasone intravitreal implant) 0.7 mg for use in adult patients with diabetic macular edema who have had an artificial lens ...

LONDON, May 21 (Reuters) - Allergan's injectable eye treatment Ozurdex won the backing of Europe's drug regulators on Friday, paving the way for the drug to be marketed in Europe in the third quarter ...

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending the dexamethasone intravitreal implant for the treatment of diabetic macular oedema (DMO). The ...

Biodegradable implant delivers extended-release corticosteroid dexamethasone via intravitreal injection. FDA cleared Allergan’s Ozurdex® 0.7 mg for noninfectious ocular inflammation, or uveitis, ...

Add Yahoo as a preferred source to see more of our stories on Google. (Reuters) - Allergan Inc said on Monday the U.S. Food and Drug Administration had raised issues about its application for a new ...